DK3002298T3 - Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number: DK3002298T3
Authority: DK; Denmark
Prior art keywords: procedures; factor; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2007-11-21

Application number

DK15189714T

Other languages

English (en)

Inventor

Andras Gruber

Erik Ian Tucker

Stephen Raymond Hanson

David Gailani

Original Assignee

Univ Oregon Health & Science

Univ Vanderbilt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-21

Filing date

2008-11-21

Publication date

2019-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3002298(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-21 Application filed by Univ Oregon Health & Science, Univ Vanderbilt filed Critical Univ Oregon Health & Science

2019-10-28 Application granted granted Critical

2019-10-28 Publication of DK3002298T3 publication Critical patent/DK3002298T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK15189714T 2007-11-21 2008-11-21 Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf DK3002298T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98952307P	2007-11-21	2007-11-21
EP08852770.0A EP2222707B1 (en)	2007-11-21	2008-11-21	Anti-factor xi monoclonal antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3002298T3 true DK3002298T3 (da)	2019-10-28

Family

ID=40568500

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08852770.0T DK2222707T3 (da)	2007-11-21	2008-11-21	Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf
DK15189714T DK3002298T3 (da)	2007-11-21	2008-11-21	Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK08852770.0T DK2222707T3 (da)	2007-11-21	2008-11-21	Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf

Country Status (16)

Country	Link
US (7)	US8236316B2 (da)
EP (2)	EP2222707B1 (da)
JP (1)	JP2011504371A (da)
AU (1)	AU2008326348B2 (da)
CA (1)	CA2705851C (da)
CY (1)	CY1122270T1 (da)
DK (2)	DK2222707T3 (da)
ES (2)	ES2755376T3 (da)
HK (1)	HK1223114A1 (da)
HR (1)	HRP20191999T1 (da)
HU (1)	HUE046564T2 (da)
LT (1)	LT3002298T (da)
PL (1)	PL3002298T3 (da)
PT (1)	PT3002298T (da)
SI (1)	SI3002298T1 (da)
WO (1)	WO2009067660A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE046564T2 (hu)	2007-11-21	2020-03-30	Univ Oregon Health & Science	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
PL2297207T3 (pl) *	2008-06-19	2019-03-29	Prothix Bv	Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
LT2379084T (lt)	2008-10-15	2018-03-26	Ionis Pharmaceuticals, Inc.	Faktoriaus 11 raiškos moduliavimas
LT2373691T (lt)	2008-12-18	2019-05-27	Oregon Health & Science University	Anti-fxi antikūnai ir jų panaudojimo būdai
US20120083522A1 (en) *	2009-04-15	2012-04-05	Isis Pharmaceuitcals, Inc.	Modulation of inflammatory responses by factor xi
CN102939098B (zh) *	2010-03-01	2016-08-03	拜耳医药保健有限公司	针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
DK2683397T3 (da) *	2011-03-09	2017-09-18	Csl Behring Gmbh	Faktor xii inhibitorer til administration til medicinske procedurer omfattende kontakt med kunstige overflader
EP2497489A1 (en) *	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2847228B1 (en) *	2012-05-10	2018-07-25	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014089493A1 (en)	2012-12-07	2014-06-12	Vanderbilt University	Antibodies against factor xii and uses thereof
CN105188535A (zh) *	2013-02-01	2015-12-23	贝克顿·迪金森公司	含有接触途径抑制添加剂的血液采集装置
EP2964255B1 (en)	2013-03-08	2020-11-04	CSL Behring GmbH	Treatment and prevention of remote ischemia-reperfusion injury
JO3565B1 (ar)	2014-08-07	2020-07-05	Novartis Ag	الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EP3194437B1 (en)	2014-08-07	2021-01-20	Novartis AG	Angiopoietin-like 4 (angptl4) antibodies and methods of use
JOP20200312A1 (ar) *	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en)	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
AU2017209083A1 (en)	2016-01-22	2018-07-12	Adimab, Llc	Anti-coagulation factor XI antibodies
AU2017236063B2 (en) *	2016-03-23	2024-06-13	Prothix Bv	Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
SG11201810763TA (en)	2016-06-14	2018-12-28	Merck Sharp & Dohme	Anti-coagulation factor xi antibodies
EP3293593B1 (en) *	2016-09-12	2019-03-20	Sandvik Intellectual Property AB	Method for estimating error propagation
RU2758160C2 (ru)	2016-09-20	2021-10-26	Байер Фарма Акциенгезельшафт	Новые антитела против фактора xi и их применения
KR102702288B1 (ko) *	2016-12-23	2024-09-05	노파르티스 아게	항-인자 XI/XIa 항체를 사용한 치료 방법
JP7139332B2 (ja) *	2016-12-23	2022-09-20	ノバルティスアーゲー	第ｘｉ因子抗体および使用方法
CN108409863B (zh) *	2017-02-10	2023-09-26	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
US11958911B2 (en)	2017-02-10	2024-04-16	Shanghai Benemae Pharmaceutical	Anti-coagulation factor XI antibody
JP2021503891A (ja) *	2017-11-22	2021-02-15	ノバルティスアーゲー	抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤およびそれらの使用
US11155638B2 (en)	2018-05-08	2021-10-26	Rhode Island Hospital	Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
JOP20200280A1 (ar)	2018-05-09	2020-11-05	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير الوراثي عن fxi
CN114478781B (zh) *	2018-08-09	2024-04-02	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
EP4177275A4 (en) *	2020-07-03	2024-07-17	Suzhou Alphamab Co., Ltd	COAGULATION FACTOR XI (FXI)-BINDING PROTEIN
WO2024141099A1 (zh) *	2022-12-30	2024-07-04	甘李药业股份有限公司	抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1319120C (en)	1985-04-01	1993-06-15	John Henry Kenten	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
DE68921982D1 (de)	1988-06-14	1995-05-04	Cetus Oncology Corp	Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en)	1989-05-05	1995-06-14	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de)	1990-03-20	1997-10-15	Univ Columbia	Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
CA2095836C (en)	1990-11-09	1999-04-06	Stephen D. Gillies	Cytokine immunoconjugates
FR2686087A1 (fr)	1992-01-13	1993-07-16	Inst Nat Sante Rech Med	Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US20030235587A1 (en)	1998-08-07	2003-12-25	Feuerstein Giora Z.	Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6623960B1 (en) *	1999-02-12	2003-09-23	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
NZ522632A (en) *	2000-05-15	2005-05-27	Smithkline Beecham Corp	Antithrombotic agents
AU2001297872B2 (en)	2000-11-17	2006-11-09	University Of Rochester	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7319139B2 (en)	2001-01-29	2008-01-15	Biogen Idec, Inc.	TAG-72 specific CH2 domain deleted antibodies
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20080138837A1 (en) *	2004-07-19	2008-06-12	Robert Greenfield	Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7780963B2 (en) *	2004-10-25	2010-08-24	Merck & Co., Inc.	Anti-ADDL antibodies and uses thereof
US7859456B2 (en)	2006-10-10	2010-12-28	Sirf Technology Holdings, Inc.	Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition
JP2010526066A (ja) *	2007-04-23	2010-07-29	シェーリングコーポレイション	抗ｍｄｌ−１抗体
HUE046564T2 (hu) *	2007-11-21	2020-03-30	Univ Oregon Health & Science	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
PL2297207T3 (pl)	2008-06-19	2019-03-29	Prothix Bv	Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
EP2373317B1 (en)	2008-11-25	2016-12-14	Merck Sharp & Dohme Corp.	4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
NZ603884A (en)	2010-05-27	2014-06-27	Merck Sharp & Dohme	Soluble guanylate cyclase activators
EP2687210A1 (de)	2010-06-25	2014-01-22	Bayer Intellectual Property GmbH	Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
CA2804470A1 (en)	2010-07-09	2012-01-12	Bayer Intellectual Property Gmbh	Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
ES2583086T3 (es)	2011-04-21	2016-09-19	Bayer Intellectual Property Gmbh	Pirazolopiridinas sustituidas con fluoroalquilo y su uso
CA2834901A1 (en)	2011-05-06	2012-11-15	Bayer Intellectual Property Gmbh	Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2013030138A1 (en)	2011-09-01	2013-03-07	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
PH12014500460A1 (en)	2011-09-02	2014-04-14	Bayer Ip Gmbh	Substituted annellated pyrimidine and the use thereof
EP2847228B1 (en)	2012-05-10	2018-07-25	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

2008
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en active Application Filing
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/da active
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
2016
- 2016-09-29 HK HK16111374.5A patent/HK1223114A1/zh unknown
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown

Also Published As

Publication number	Publication date
EP3002298B1 (en)	2019-08-28
CA2705851A1 (en)	2009-05-28
US20130171144A1 (en)	2013-07-04
EP2222707A2 (en)	2010-09-01
HRP20191999T1 (hr)	2020-02-07
AU2008326348A1 (en)	2009-05-28
ES2755376T3 (es)	2020-04-22
US8399648B2 (en)	2013-03-19
HK1223114A1 (zh)	2017-07-21
WO2009067660A2 (en)	2009-05-28
WO2009067660A3 (en)	2009-07-09
US20140322219A1 (en)	2014-10-30
ES2566963T3 (es)	2016-04-18
CY1122270T1 (el)	2020-11-25
US8236316B2 (en)	2012-08-07
US20120276112A1 (en)	2012-11-01
EP3002298A1 (en)	2016-04-06
US9125895B2 (en)	2015-09-08
US20110020349A1 (en)	2011-01-27
JP2011504371A (ja)	2011-02-10
SI3002298T1 (sl)	2019-12-31
AU2008326348B2 (en)	2014-01-30
LT3002298T (lt)	2019-12-10
US20170204195A1 (en)	2017-07-20
US20180355057A1 (en)	2018-12-13
US20150322163A1 (en)	2015-11-12
EP2222707B1 (en)	2016-01-06
US10577428B2 (en)	2020-03-03
US9636399B2 (en)	2017-05-02
HUE046564T2 (hu)	2020-03-30
DK2222707T3 (da)	2016-04-11
CA2705851C (en)	2016-11-01
PT3002298T (pt)	2019-11-20
PL3002298T3 (pl)	2020-03-31

Publication	Publication Date	Title
DK3002298T3 (da)	2019-10-28	Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
DK2907827T3 (da)	2019-01-02	Humaniserede anti-faktor D-antistoffer og anvendelser deraf
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2283041T3 (da)	2015-12-07	Humaniserede anti-faktor d-antistoffer og anvendelser deraf
LTC2379594I2 (lt)	2020-04-10	Žmogaus CGRP receptorių rišantys antikūnai
DK1994055T3 (da)	2014-08-25	Anti-5t4-antistoffer og anvendelser deraf
DK2152748T3 (da)	2013-11-04	Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2474557T3 (da)	2014-11-10	Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
DK2209806T3 (da)	2012-09-17	Anti-hepcidin-antistoffer og anvendelser deraf
DK2059535T3 (da)	2014-01-13	Prlr-specifikt antistof og anvendelser deraf
DK3401334T3 (da)	2023-03-27	Monoklonale antistoffer mod claudin-18 til cancerbehandling
NO344963B1 (no)	2020-08-03	Humanisert antistoff
BRPI0822447A2 (pt)	2015-06-16	Anticorpo monoclonal e método do mesmo
DK2068887T3 (da)	2014-05-19	SP35-antistoffer og anvendelser heraf
DK2061814T3 (da)	2012-08-27	Antistoffer og immunokonjugater og anvendelse deraf.
DK1996625T3 (da)	2011-11-28	Anti-Tat226 antistoffer og immunkonjugater
BRPI0820298A2 (pt)	2017-04-04	anticorpos anti-vegf composições e métodos
DK2209375T3 (da)	2014-10-06	Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
BRPI0914943A2 (pt)	2013-09-17	anticorpos de il-6 e sua utilizaÇço
DK2032606T3 (da)	2014-02-03	Antistoffer og immunkonjugater og anvendelser deraf
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
DK2158217T3 (da)	2014-04-07	Humant monoklonalt antistof, der neutraliserer vaskulær endotel vækstfaktorreceptor, og anvendelse heraf
FI20070853A0 (fi)	2007-11-09	Glykaania sitovat monoklonaaliset vasta-aineet